Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;6(2):5.
doi: 10.1007/s40137-018-0202-0. Epub 2018 Feb 8.

Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence?

Christopher M Jones  1   2   3 , Alessandro Brunelli  4 , Matthew E Callister  5 , Kevin N Franks  1   2
Affiliations
Review

Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence?

Christopher M Jones et al. Curr Surg Rep. 2018.

Abstract

Purpose of review: The majority of patients with non-small cell lung cancer (NSCLC) present with advanced disease and overall survival rates are poor. This article outlines the current and outstanding evidence for the use of multimodality treatment in this group of patients, including in combination with an increasing number of treatment options, such as immunotherapy and genotype-targeted small molecule inhibitors.

Recent findings: Optimal therapy for surgically resectable stage III disease remains debatable and currently the choice of treatment reflects each individual patient's disease characteristics and the expertise and opinion of the thoracic multi-disciplinary team. Evidence for a distinct oligometastatic state in which improved outcomes can be achieved remains minimal and there is as yet no consensus definition for oligometastatic lung cancer. Whilst there is supporting evidence for the aggressive management of isolated metastases, the use of consolidative therapy for multiple metastases remains unproven.

Summary: Evolution of new RT technologies, improved surgical technique and a plethora of interventional-radiology-guided ablative therapies are widening the choice of available treatment modalities to patients with NSCLC. In the setting of resectable locally advanced disease and the oligometastatic state, there is a growing need for randomised comparison of the available treatment modalities to guide both treatment and patient selection.

Keywords: Chemotherapy; Locally advanced; Lung cancer; Oligometastatic; Radiotherapy; Stereotactic ablative radiotherapy; Surgery; Treatment.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethics GuidelinesThe authors declare no conflicts of interest relevant to this manuscript.This article does not contain any studies with human or animal subjects performed by any of the authors.

References

    1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwie: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed 01 Aug 2017.
    1. Bierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8. Hoboken: Wiley; 2017.
    1. •• Postmus PE, Kerr KM, Oudkerk M et al. Early-stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines. Ann Oncol 2017;28(suppl 4):iv1–21. Current European guidelines for the management of patients with locally advanced non-small-cell lung cancer. - PubMed
    1. Rosen JE, Keshava HB, Yao X, et al. The natural history of operable NSCLC in the National Cancer Database. Ann Thorac Surg. 2016;101:1850–1855. doi: 10.1016/j.athoracsur.2016.01.077. - DOI - PubMed
    1. • Cortes AA, Urguizu LC, Cubero JH. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Trans Lung Cancer Res 2015;4(2):191–7. Comprehensive overview of current evidence for the use of adjuvant chemotherapy in NSCLC. - PMC - PubMed